Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.81 |
| ▸ | CCR4 | P51679 | 1/20 | 0.64 |
| ▸ | NSD2 | O96028 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | EHMT1 | Q9H9B1 | 7/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17122602 | 0.93 | EHMT2 (0.76) | EHMT2CCR4NSD2EHMT1 | |
| SCHEMBL15280231 | 0.93 | EHMT2 (0.76) | EHMT2CCR4NSD2EHMT1 | |
| SCHEMBL12526929 | 0.91 | EHMT2 (0.72) | EHMT2CCR4NSD2HTTEHMT1 | |
| Hydrochloric Acid SCHEMBL1748340 | 0.90 | EHMT2 (0.71) | EHMT2CCR4NSD2HTTEHMT1 | |
| SCHEMBL29809532 | 0.90 | EHMT2 (1.00) | EHMT2NSD2EHMT1 | |
| Hydrochloric Acid SCHEMBL23360133 | 0.90 | EHMT2 (0.71) | EHMT2CCR4NSD2HTTEHMT1 | |
| Hydrochloric Acid SCHEMBL29862852 | 0.90 | EHMT2 (0.71) | EHMT2CCR4NSD2HTTEHMT1 | |
| SCHEMBL15280254 | 0.90 | EHMT2 (1.00) | EHMT2NSD2EHMT1 | |
| SCHEMBL31298948 | 0.88 | EHMT2 (0.68) | EHMT2CCR4NSD2HTTEHMT1 | |
| SCHEMBL31016438 | 0.88 | EHMT2 (0.79) | EHMT2CCR4NSD2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346848-B1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8318749-B2 | Quinazoline derivatives as NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125078-A1 | QUINAZOLINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | SLC6A3, OPRK1, HTR3A | EHMT2 3673/4885CCR4 2953/4885NSD2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.